Actively Recruiting
Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines
Led by JHM BioPharma (Tonghua) Co. , Ltd. · Updated on 2025-09-02
669
Participants Needed
15
Research Sites
65 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase 3 clinical study to evaluate the efficacy, safety, and immunogenicity of single/repeated injections of Eveotox in the treatment of moderate to severe glabellar lines. The study consists of Study Part 1 (randomized double-blind controlled study) and Part 2 (open-label study). Part I is a multicenter, randomized, double-blind, single-injection, active-controlled and placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of Eveotox in the treatment of moderate to severe glabellar lines; Part 2 is an open-label study to evaluate the efficacy, safety, and immunogenicity of repeated injections of Eveotox in the treatment of moderate to severe glabellar lines.
CONDITIONS
Official Title
Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female subjects who are between 18 to 65 years of age
- Moderate or severe glabellar lines during maximum frown based on the Investigator Global Assessment Frown Wrinkle Severity scale
- Moderate or severe glabellar lines during maximum frown based on the Patient Frown Wrinkle Severity scale
- Willing and able to follow all trial procedures, attend all scheduled visits, and successfully complete the trial
You will not qualify if you...
- History of oversensitivity to Botulinum Toxin A type or other components of the study drug
- Implanted permanent materials in the glabellar area or received semi-permanent fillers within 2 years of screening
- Active skin infections at the injection site or systemic skin disease affecting evaluation
- History of injecting drugs similar to the study drug within 6 months prior to selection or expected use during the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 15 locations
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
2
Peking University First Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
3
Peking University Third Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
4
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Actively Recruiting
5
The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China
Actively Recruiting
6
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Actively Recruiting
7
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Actively Recruiting
8
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China
Actively Recruiting
9
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
Actively Recruiting
10
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Actively Recruiting
11
Xianyang Hospital of Yan'an University
Xianyang, Shanxi, China
Actively Recruiting
12
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Actively Recruiting
13
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Actively Recruiting
14
Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University
Hangzhou, Zhejiang, China
Actively Recruiting
15
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
Actively Recruiting
Research Team
D
Danhua Lin
CONTACT
L
Lei Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here